Clinical Trials Logo

Colorectal Cancer clinical trials

View clinical trials related to Colorectal Cancer.

Filter by:

NCT ID: NCT05740137 Active, not recruiting - Colorectal Cancer Clinical Trials

Adenoma Detection Rate in Artificial Intelligence-assisted Colonoscopy

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

The goal of this cluster randomized multicenter controlled clinical trial (RCT) is to investigate whether a combined real time computer-aided polyp detection (CADe) and computer-aided polyp characterization (CADx) system (GI Genius, Medtronic) can increase the adenoma detection rate (ADR) and reduce the performance variability among endoscopists. Participants will be randomized (1:1) to either receive an AI-assisted colonoscopy (AIC) or a conventional colonoscopy (CC). If there is a comparison group: Researchers will compare the AIC-group and the CC-group to see if AIC can increase the ADR significantly.

NCT ID: NCT05693519 Active, not recruiting - Colorectal Cancer Clinical Trials

GastroIntestinal Cancer in Children and Adolescents

GICCA
Start date: December 22, 2022
Phase:
Study type: Observational

The goal of this observational population-based cohort study is to investigate the clinical characteristics and outcomes of children and adolescents with primary gastrointestinal malignancies registered in the publicly available Surveillance, Epidemiology, and End Results (SEER) 17 database during 2000-2019.

NCT ID: NCT05678257 Active, not recruiting - Colorectal Cancer Clinical Trials

A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

Start date: April 18, 2023
Phase: Phase 2
Study type: Interventional

This is a randomized, open-label, dose/schedule optimization study comparing NUC-3373/leucovorin (LV)/irinotecan plus bevacizumab (NUFIRI-bev) to 5-FU/LV/irinotecan plus bevacizumab (FOLFIRI-bev) for the treatment of patients with unresectable metastatic colorectal cancer. A total of 171 patients will be randomized 1:1:1 to either NUFIRI-bev on a weekly NUC-3373 schedule, NUFIRI-bev based on an alternate weekly NUC-3373 schedule, or FOLFIRI bev on an alternate weekly schedule. The main objectives are to assess and compare the efficacy and safety of the 3 regimens. Pharmacokinetics will be assessed on the 2 NUFIRI arms.

NCT ID: NCT05661357 Active, not recruiting - Colorectal Cancer Clinical Trials

Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression

HCCSC-C03
Start date: January 1, 2023
Phase: Phase 4
Study type: Interventional

Single arm, prospective, exploratory clinical study of Disitamab Vedotin combined with Fruquintinib for advanced colorectal cancer with HER2 expression or mutation that has received at least two standard treatment failures

NCT ID: NCT05638542 Active, not recruiting - Colorectal Cancer Clinical Trials

Comparison of Expression of Carcinogenesis-related Molecular Markers in the Patients With Colon Cancer and Polyp

Start date: March 1, 2015
Phase:
Study type: Observational

A study of carcinogenesis-related molecular markers in the patients with colorectal cancer and colorectal adenoma.

NCT ID: NCT05619172 Active, not recruiting - Colorectal Cancer Clinical Trials

A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer

Start date: December 22, 2022
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa (SOT101) in combination with cetuximab in RAS wild-type colorectal cancer.

NCT ID: NCT05600309 Active, not recruiting - Colorectal Cancer Clinical Trials

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

Start date: June 14, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this China extension study is to assess the safety and efficacy of coformulated favezelimab/pembrolizumab (MK-4280A) in adult Chinese participants with metastatic colorectal cancer. The study will also compare MK-4280A with the standard of care treatment of regorafenib and TAS-102 (trifluridine and tipiracil). The primary study hypothesis is that coformulated favezelimab/pembrolizumab (MK-4280A) is superior to standard of care with respect to overall survival.

NCT ID: NCT05593328 Active, not recruiting - Colorectal Cancer Clinical Trials

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Start date: March 17, 2023
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to assess the efficacy of 2 different doses of onvansertib in combination with a chemotherapy regimen of irinotecan, fluorouracil [5-FU], and leucovorin (FOLFIRI) and bevacizumab for treatment of confirmed metastatic and/or unresectable colorectal cancer (CRC) in participants with a kirsten rat sarcoma virus gene (KRAS) or neuroblastoma-RAS (NRAS) mutation who have progressed on an oxaliplatin/fluoropyrimidinebased regimen in the first-line setting.

NCT ID: NCT05551052 Active, not recruiting - Colorectal Cancer Clinical Trials

CRC Detection Reliable Assessment With Blood

CRC-DRAW
Start date: September 8, 2022
Phase:
Study type: Observational

The CRC DRAW study will assess the sensitivity and specificity of the blood-based, Next-Gen CRC Screening Test for the detection of CRC.

NCT ID: NCT05546476 Active, not recruiting - Colorectal Cancer Clinical Trials

Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15

PROACC-1
Start date: November 21, 2022
Phase: Phase 2
Study type: Interventional

Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.